Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study

Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis

(2020) Rod S. Taylor et al.   GASTROENTEROLOGY

Advances in non-invasive assessment of hepatic fibrosis

(2020) Rohit Loomba et al.   GUT

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

(2020) Philip N Newsome et al.   Lancet Gastroenterology & Hepatology

Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States

(2020) Zobair M. Younossi et al.   Clinical Gastroenterology and Hepatology

Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials

(2020) Beth A. Davison et al.   JOURNAL OF HEPATOLOGY

Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood‐based fibrosis markers in patients with chronic liver disease

(2020) Arjun N.A. Jayaswal et al.   LIVER INTERNATIONAL

Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease

(2019) Ankur Srivastava et al.   JOURNAL OF HEPATOLOGY

Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD

(2019) Mary E. Rinella et al.   JOURNAL OF HEPATOLOGY

Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease

(2019) Katharina Staufer et al.   United European Gastroenterology Journal

REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis

(2019) Vlad Ratziu et al.   Contemporary Clinical Trials

Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy

(2019) Rui Huang et al.   DIGESTIVE DISEASES AND SCIENCES

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2019) Stephen A Harrison et al.   LANCET

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances

(2018) Mazen Noureddin et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Relationship Between Three Commonly Used Non-invasive Fibrosis Biomarkers and Improvement in Fibrosis Stage in Patients With NASH

(2018) Naga Chalasani et al.   LIVER INTERNATIONAL

Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis

(2018) Rohit Loomba et al.   GASTROENTEROLOGY

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

(2017) Parambir S. Dulai et al.   HEPATOLOGY

Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease

(2016) William N. Hannah et al.   Clinics in Liver Disease

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

(2016) Frederik Nevens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?

(2016) Jun L. Chin et al.   Frontiers in Pharmacology

Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease

(2015) Elif Dincses et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

(2015) Paul Angulo et al.   GASTROENTEROLOGY

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management

(2015) Stuart McPherson et al.   JOURNAL OF HEPATOLOGY

Noninvasive Evaluation of Liver Fibrosis Using Real-time Tissue Elastography and Transient Elastography (FibroScan)

(2015) Fankun Meng et al.   JOURNAL OF ULTRASOUND IN MEDICINE

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease

(2015) Katharine M. Irvine et al.   LIVER INTERNATIONAL

Bile acid nuclear receptor FXR and digestive system diseases

(2015) Lili Ding et al.   Acta Pharmaceutica Sinica B

Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

(2013) Paul Angulo et al.   GASTROENTEROLOGY

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values

(2013) Ralf Lichtinghagen et al.   JOURNAL OF HEPATOLOGY

Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease

(2013) Rajarshi Banerjee et al.   JOURNAL OF HEPATOLOGY

Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease

(2012) Sudeep Tanwar et al.   HEPATOLOGY

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

(2011) R. M. Gadaleta et al.   GUT

Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

(2009) Amy G. Shah et al.   Clinical Gastroenterology and Hepatology